Top Story

Long-term inhaled corticosteroid use linked to hip fracture risk

Long-term inhaled corticosteroid use linked to hip fracture risk
March 5, 2018
FDA News

FDA approves Daliresp 250 µg as starting dose for severe COPD

January 26, 2018
AstraZeneca recently announced that the FDA has approved once-daily Daliresp 250 µg as a starting dose for the initial 4 weeks followed by 500 µg to reduce treatment…
In the Journals

Inhaled long-acting bronchodilator use in COPD increases CVD risk

January 4, 2018
New use of long-acting beta 2-agonists and long-acting muscarinic antagonists in patients with COPD was associated with a 1.5-fold increased risk for cardiovascular…
In the JournalsPerspective

Steroid inhaler use increases risk for hard-to-treat lung infections

October 20, 2017
Older adults who were treated for asthma or COPD with inhaled corticosteroids were twice as likely to develop nontuberculous mycobacterial pulmonary disease infections…
More Headlines »
CME Article

Origins of Outcome Disparities in Pediatric Respiratory Disease

Pediatric Annals, December 2010, Volume 39 Issue 12
Respiratory diseases account for a significant portion of morbidity and mortality in pediatric medicine, but this…
More »
Meeting News

VIDEO: MedImmune collaborations produce three discoveries in COPD

October 28, 2016
More »